Get started
Home/Weight Management/Tirzepatide/B6 12.5mg/50mg/mL
Weight Management Tirzepatide/B6 12.5mg/50mg/mL Injectable vial
Weight Management

Tirzepatide/B6 12.5mg/50mg/mL

$405/month
Free shipping · Reviewed by a licensed clinician · Cancel anytime
FDA-registered pharmacy
Compounded in a licensed facility
Batch tested
Potency and sterility verified
Cold-chain shipping
Temperature controlled delivery
How it works
Three steps to your treatment
1
Complete your intake
Answer questions about your health history, lifestyle, and goals.
About 5 minutes
2
Clinician review
Our licensed clinicians evaluate your intake and prescribe your treatment.
Within 24 hours
3
Receive your treatment
Delivered to your door in 2 days, free shipping included.
2-day delivery
About this treatment
What is Tirzepatide/B6 Injectable?

Tirzepatide is a dual GLP-1/GIP receptor agonist that targets both major incretin pathways for weight management. Enhanced with vitamin B6 for metabolic support during treatment.

Benefits
Key benefits
Dual Receptor Action
Activates both GLP-1 and GIP receptors for enhanced metabolic effect.
Superior Appetite Control
Greater appetite reduction than single-incretin therapies.
Insulin Sensitivity
Improves beta-cell function and glucose-dependent insulin secretion.
Enhanced B6 Formula
High-dose B6 supports energy metabolism during caloric restriction.
Dosage
Treatment protocol
Dosing Your dosage is determined by your provider during your medical evaluation. Dosage may be adjusted over time based on your progress and response to treatment.
Frequency As prescribed based on your intake assessment
Administration Subcutaneous injection
Supplies Included with your prescription shipment
Included with your prescription
Eligibility
Is Tirzepatide/B6 Injectable Right for You?
May be appropriate for
  • Adults with BMI 30+ or BMI 27+ with weight-related comorbidities
  • Individuals seeking dual-action incretin therapy under medical supervision
  • Those who may benefit from enhanced GIP/GLP-1 pathway activation
Not recommended for
  • Individuals with personal or family history of medullary thyroid carcinoma or MEN2
  • Pregnant or breastfeeding individuals
  • Those with a history of severe pancreatitis or gastroparesis
Research
Clinical references
Jastreboff AM, et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
Frias JP, et al. (2021) "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)" New England Journal of Medicine. DOI: 10.1056/NEJMoa2107519
Rosenstock J, et al. (2021) "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (SURPASS-1)" The Lancet. DOI: 10.1016/S0140-6736(21)01324-6
Questions
Frequently asked questions
How does tirzepatide differ from semaglutide? +
Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide targets only GLP-1. This dual mechanism has shown greater weight reduction in clinical trials. Your provider will help determine which option is best suited to your medical history and goals.
What are the most common side effects? +
Gastrointestinal effects such as nausea, diarrhea, and decreased appetite are the most commonly reported. These tend to be mild to moderate and typically improve as your body adjusts. Gradual dose titration helps minimize these effects.
How quickly can I expect results? +
Appetite reduction is often noticeable within the first week. Clinically significant weight changes are typically observed within 4-12 weeks depending on starting dose, titration schedule, and individual metabolic factors.
Is this a compounded medication? +
Yes, this is a compounded formulation prepared by a licensed U.S. pharmacy combining tirzepatide with vitamin B6. All compounding follows strict FDA-regulated quality standards.

Ready to start?

Clinician-supervised, delivered to your door.